ArticleNeuro-oncology2013
Serum-free culture success of glial tumors is related to specific molecular profiles and expression of extracellular matrix-associated gene modules.
Article in Neuro-oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed.
- Exploring the landscape of targetable alterations in patients with glioblastoma.Nature reviews. Clinical oncology · 2026Review
- Optimized culturing yields high success rates and preserves molecular heterogeneity, enabling personalized screening for high-grade gliomas.NPJ precision oncology · 2025Article
- Article
- Advancing humanized 3D tumor modeling using an open access xeno-free medium.Frontiers in toxicology · 2025Article
- Two-Step Transfer Learning Improves Deep Learning-Based Drug Response Prediction in Small Datasets: A Case Study of Glioblastoma.Bioinformatics and biology insights · 2025Article
- BMP4 and Temozolomide Synergize in the Majority of Patient-Derived Glioblastoma Cultures.International journal of molecular sciences · 2024Article
- An autologous ex vivo model for exploring patient-specific responses to viro-immunotherapy in glioblastoma.Cell reports methods · 2024Article
- Expressions of the satellite repeat HSAT5 and transposable elements are implicated in disease progression and survival in glioma.Turkish journal of biology = Turk biyoloji dergisi · 2024Article
- Genomic Exploration of Distinct Molecular Phenotypes Steering Temozolomide Resistance Development in Patient-Derived Glioblastoma Cells.International journal of molecular sciences · 2023Article
- Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers.British journal of cancer · 2023Article
- Modeling glioblastoma complexity with organoids for personalized treatments.Trends in molecular medicine · 2023Review
- Glioblastoma modeling with 3D organoids: progress and challenges.Oxford open neuroscience · 2023Review
- Glioblastoma, from disease understanding towards optimal cell-based in vitro models.Cellular oncology (Dordrecht, Netherlands) · 2022Review
- Drug Repurposing, a Fast-Track Approach to Develop Effective Treatments for Glioblastoma.Cancers · 2022Review
- Nonhuman Primate Adenoviruses of the Human Adenovirus B Species Are Potent and Broadly Acting Oncolytic Vector Candidates.Human gene therapy · 2022Article
- Effects of the IDH1 R132H Mutation on the Energy Metabolism: A Comparison between Tissue and Corresponding Primary Glioma Cell Cultures.ACS omega · 2022Article
- Novel kinome profiling technology reveals drug treatment is patient and 2D/3D model dependent in glioblastoma.Frontiers in oncology · 2022Article
- Opportunities and challenges of glioma organoids.Cell communication and signaling : CCS · 2021Review
- Transcriptional CDK inhibitors, CYC065 and THZ1 promote Bim-dependent apoptosis in primary and recurrent GBM through cell cycle arrest and Mcl-1 downregulation.Cell death & disease · 2021Article
- Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist.Cell death & disease · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent molecular characterization studies have identified clinically relevant molecular subtypes to coexist within the same histological entities of glioma. Comparative studies between serum-supplemented and serum-free (SF) culture conditions have demonstrated that SF conditions select for glioma stem-like cells, which superiorly conserve genomic alterations. However, neither the representation of molecular subtypes within SF culture assays nor the molecular distinctions between successful and nonsuccessful attempts have been elucidated.
methodsA cohort of 261 glioma samples from varying histological grades was documented for SF culture success and clinical outcome. Gene expression and single nucleotide polymorphism arrays were interrogated on a panel of tumors for comparative analysis of SF+ (successful cultures) and SF- (unsuccessful cultures).
resultsSF culture outcome was correlated with tumor grade, while no relation was found between SF+ and patient overall survival. Copy number-based hierarchical clustering revealed an absolute separation between SF+ and SF- parental tumors. All SF+ cultures are derived from tumors that are isocitrate dehydrogenase 1 (IDH1) wild type, chromosome 7 amplified, and chromosome 10q deleted. SF- cultures derived from IDH1 mutant tumors demonstrated a fade-out of mutated cells during the first passages. SF+ tumors were enriched for The Cancer Genome Atlas Classical subtype and intrinsic glioma subtype-18. Comparative gene ontology analysis between SF+ and SF- tumors demonstrated enrichment for modules associated with extracellular matrix composition, Hox-gene signaling, and inflammation.
conclusionSF cultures are derived from a subset of parental tumors with a shared molecular background including enrichment for extracellular matrix-associated gene modules. These results provide leads to develop enhanced culture protocols for glioma samples not propagatable under current SF conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.